scholarly journals Left ventricular mass reduction during salt depletion in arterial hypertension.

Hypertension ◽  
1984 ◽  
Vol 6 (5) ◽  
pp. 755-759 ◽  
Author(s):  
L A Ferrara ◽  
G de Simone ◽  
F Pasanisi ◽  
M Mancini ◽  
M Mancini
Keyword(s):  
Arterial Hypertension ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Mass Reduction ◽  
Ventricular Mass ◽  
Salt Depletion

scholarly journals The "Pulse Time Index of Norm" highly correlates with the left ventricular mass index in patients with arterial hypertension

2014 ◽  
pp. 139 ◽  
Author(s):  
Igor Posokhov ◽  
Natalya Kulikova ◽  
Irina Starchenkova ◽  
Elena Grigoricheva ◽  
Vitaly Evdokimov ◽  
...  
Keyword(s):  
Arterial Hypertension ◽  
Left Ventricular Mass ◽  
Left Ventricular Mass Index ◽  
Left Ventricular ◽  
Pulse Time ◽  
Ventricular Mass Index ◽  
Time Index ◽  
Ventricular Mass

Initial left-ventricular mass predicts probability of uncontrolled blood pressure in arterial hypertension

2011 ◽  
Vol 29 (4) ◽  
pp. 803-808 ◽  
Author(s):  
Raffaele Izzo ◽  
Giovanni de Simone ◽  
Richard B Devereux ◽  
Renata Giudice ◽  
Marina De Marco ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Arterial Hypertension ◽  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Uncontrolled Blood Pressure ◽  
Ventricular Mass

scholarly journals ARTERIAL HYPERTENSION ASSOCIATED WITH HYPERURICEMIA: FEATURES OF HEART DAMAGE

2020 ◽  
Vol 73 (5) ◽  
pp. 943-946
Author(s):  
Olha M. Chernatska ◽  
Liudmyla N. Prystupa ◽  
Hanna A. Fadieieva ◽  
Alina V. Liashenko ◽  
Yuliia O. Smiianova
Keyword(s):  
Uric Acid ◽  
Left Ventricular Hypertrophy ◽  
Arterial Hypertension ◽  
Left Ventricular Mass ◽  
Ventricular Hypertrophy ◽  
Left Ventricular Mass Index ◽  
Serum Uric Acid Level ◽  
Left Ventricular ◽  
Ventricular Mass Index ◽  
Ventricular Mass

The aim is the analysis of hyperuricemia influence on the heart features in patients with arterial hypertension. Materials and methods: We include 75 patients with arterial hypertension which were divided in two groups according to the level of uric acid in the blood, 30 practically healthy people. Patients from the I group (n = 40) had arterial hypertension and coexistent hyperuricemia; ІІ (n = 35) – arterial hypertension. Left ventricular mass index was determined for left ventricular hypertrophy confirmation. We used clinical, anthropometric, biochemical, instrumental, statistical method. Serum uric acid level was observed by the reaction with uricase. Left ventricular mass index was calculated as left ventricular mass to body surface area ratio. The results were analyzed statistically by SPSS 21 and Graphpad. Results: Left ventricular mass index was significantly higher (р = 0,0498) in patients from the І group (109,7 ± 3,21) g/m2 comparable with the ІІ (97,6 ± 5,35) g/m2 and increased in proportion to the biggest level of uric acid (r = 0,31; p = 0,04) in patients with arterial hypertension and hyperuricemia. Conclusions: Concentric and excentric left ventricular hypertrophy, increased left ventricular mass index proportionally to uric acid levels (r = 0,31; p = 0,04) is the confirmation of important role of hyperuricemia in the left ventricular hypertrophy development in patients with arterial hypertension.

scholarly journals No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy

2006 ◽  
Vol 111 (6) ◽  
pp. 365-372 ◽  
Author(s):  
Wolfgang Lieb ◽  
Juliane Bolbrinker ◽  
Angela Döring ◽  
Hans-Werner Hense ◽  
Jeanette Erdmann ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Arterial Hypertension ◽  
Left Ventricular Mass ◽  
Posterior Wall ◽  
Pressure Control ◽  
Population Based ◽  
Left Ventricular ◽  
Genotype Distribution ◽  
Cytochrome P450 3A ◽  
Ventricular Mass

A polymorphism in the cytochrome P450 3A CYP3A5 enzyme has been implicated in BP (blood pressure) control and arterial hypertension. Carriers of the CYP3A5*1 allele had high, whereas homozygous carriers of the CYP3A5*3 allele exhibit low, CYP3A5 expression in the kidney, where CYP3A5 represents the major CYP3A enzyme. The aim of the present study was to investigate the association of the CYP3A5*1 allele with BP, arterial hypertension, LVM [(left ventricular) mass] and LV geometry in a large Caucasian-population-based cohort. We compared BP, LVM and the prevalence of hypertension between carriers (CYP3A5*1/*1 and CYP3A5*1/*3 genotypes) and non-carriers (CYP3A5*3/*3 genotype) of the CYP3A5*1 allele in the echocardiographic substudy of the third MONICA (MONItoring trends and determinants in CArdiovascular disease) Augsburg survey. After exclusion of 269 individuals who were taking antihypertensive medication, 530 women and 554 men were available for analysis, revealing allele frequencies of 5.8 and 94.2% for the CYP3A5*1 and CYP3A5*3 alleles respectively. Overall, the presence of the CYP3A5*1 allele exhibited no effect on systolic or diastolic BP in either gender. One-third of the individuals in this cohort were hypertensive (BP ≥140/90 mmHg), and the genotype distribution between normotensive and hypertensive individuals revealed no association between CYP3A5*1 and hypertension after adjustment for age, BMI and gender (odds ratio, 1.02; P=0.92). Moreover, no effect of CYP3A5*1 on LVM, thickness of the septal and posterior wall and LV end-diastolic diameter was found. We conclude that CYP3A5*1 exhibits no significant effect on BP, LVM and LV geometry in the KORA/MONICA echocardiographic substudy.

scholarly journals Left Ventricular Mass Reduction in Type 1 Diabetic Patients With Nephropathy

2005 ◽  
Vol 7 (3) ◽  
pp. 159-164 ◽  
Author(s):  
Larry A. Weinrauch ◽  
Andrew Burger ◽  
Ray E. Gleason ◽  
Annette T. Lee ◽  
John A. D'Elia
Keyword(s):  
Left Ventricular Mass ◽  
Left Ventricular ◽  
Diabetic Patients ◽  
Mass Reduction ◽  
Ventricular Mass ◽  
Type 1 Diabetic Patients
Sign in / Sign up

Export Citation Format

Share Document